Response to Crizotinib in Infantile Fibrosarcoma with <i>TFG::MET</i> Gene Fusion
A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing.
Authors
- Michael Krivanek
- Natacha Omer (ORCID: https://orcid.org/0000-0002-5643-1307)
- Luciano Dalla‐Pozza (ORCID: https://orcid.org/0000-0001-6826-764X)
- Kevin Hardin
- Bruce Goodwin
- Dr Wayne Nicholls
- Dale Wright
- Martin Lowe
- Ashleigh Sullivan (ORCID: https://orcid.org/0009-0004-3818-0614)
- Shampavi Sri Haran
- Jane McEniery
- Artur Darmanian
- Lucy Cain
Institutions
- Queensland Health (AU)
- Children's Hospital of Philadelphia (US)
- Children's Hospital at Westmead (AU)
- Children's Health Queensland Hospital and Health Service (AU)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1056/nejmc2518422
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00